Monday’s Highlights at Noon: Clovis Oncology (CLVS), Bluebird Bio (BLUE), Cormedix (CRMD), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN)

So far Monday, November 11, NASDAQ is down -0.16% and the S&P is up 0.76%. Here are this morning’s most active stocks: Clovis Oncology (CLVSResearch Report), Bluebird Bio (BLUEResearch Report), Cormedix (CRMDResearch Report), ACADIA Pharmaceuticals (ACADResearch Report) and Amarin (AMRNResearch Report).

Clovis Oncology is down -7.97% in midday trading to $5.54. Shares opened today at $6.02. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $12.56, marking a 108.64% potential upside from current levels. In a report issued on November 8, Evercore ISI analyst Joshua Schimmer maintained a Buy rating on CLVS, with a price target of $12.00, which represents a potential upside of 99% from where the stock is currently trading. Separately, on November 7, Piper Jaffray’s Joseph Catanzaro reiterated a Hold rating on the stock and has a price target of $4.50. Over the last 3 months, the insider sentiment on Clovis Oncology has been positive based on 42 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Bluebird Bio is down -7.13% in midday trading to $72.21. Shares opened today at $77.75. The company has a 52-week low of $72.02 and a 52-week high of $163.43. On the Street’s front, the average 12-month analyst price target for the stock is $117.83, marking a 51.55% potential upside from current levels. In a report issued on November 4, Wedbush analyst David Nierengarten upgraded BLUE to Buy, with a price target of $124.00, which implies an upside of 59% from current levels. Separately, on November 1, Morgan Stanley’s Matthew Harrison maintained a Hold rating on the stock and has a price target of $100.00.

Cormedix is up 6.47% in midday trading to $5.63. Shares opened today at $5.29. The company has a 52-week low of $4.20 and a 52-week high of $13.70. On the Street’s front, the average 12-month analyst price target for the stock is $14.00, marking a 164.65% potential upside from current levels. In a report issued on October 17, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CRMD, with a price target of $14.00, which represents a potential upside of 165% from where the stock is currently trading. Over the last 3 months, the insider sentiment on Cormedix has been positive based on 30 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

ACADIA Pharmaceuticals is up 5.34% in midday trading to $45.03. Shares opened today at $42.75. The company has a 52-week low of $14.01 and a 52-week high of $45.22. On the Street’s front, the average 12-month analyst price target for the stock is $52.64, marking a 23.13% potential upside from current levels. In a report issued on November 7, J.P. Morgan analyst Cory Kasimov maintained a Hold rating on ACAD, with a price target of $35.00, which implies a downside of 18% from current levels. Separately, on November 1, H.C. Wainwright’s Andrew Fein reiterated a Buy rating on the stock and has a price target of $60.00. In the last 30 days, insiders purchased $199.8K worth of ACAD shares. Over the last 3 months, the insider sentiment on ACADIA Pharmaceuticals has been neutral based on 14 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Amarin is down -5.1% in midday trading to $16.84. Shares opened today at $17.74. The company has a 52-week low of $11.78 and a 52-week high of $23.91. On the Street’s front, the average 12-month analyst price target for the stock is $29.11, marking a 64.09% potential upside from current levels. In a report issued on November 6, Citigroup analyst Joel Beatty reiterated a Buy rating on AMRN, with a price target of $23.00, which represents a potential upside of 30% from where the stock is currently trading. Separately, on October 29, Goldman Sachs’ Paul Choi reiterated a Hold rating on the stock and has a price target of $17.00. In the last 30 days, insiders purchased $29K worth of AMRN shares. Over the last 3 months, the insider sentiment on Amarin has been positive based on 64 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.